Value of Color Doppler Ultrasonography for Diagnosing Early Diabetic Nephropathy.

INTRODUCTION: Early diagnosis of diabetic nephropathy (DN), the leading cause of death in diabetic patients, is an important issue in preventing and reducing the disease burden for patients and the healthcare system. In this study, we aimed at investigating the value of color doppler ultrasonography in the diagnosis of early diabetic nephropathy (DN). METHODS: Two hundred and thirty-eight diabetic patients, were enrolled in this study and were categorized into, either control (n = 109) or study group (n = 129), according to 24 hours urinary albumin excretion rate (UAER), from January 2015 to March 2021. The morphologic findings of the kidneys were observed and compared, in both groups, by color doppler ultrasound technique, and blood flow of renal arteries was also measured, at all levels. Fasting plasma glucose (FPG), uric acid, homocysteine, beta-2- microglobulin, cystatin C, hemoglobin A1c (HbA1c) and CRP were also extracted from their laboratory results. RESULTS: Compared to the control group, the study group had lower intrarenal arterial end-diastolic blood flow velocity (EDV) and higher arterial resistance index (RI) (P ~ < .05). A significant diagnostic value of intrarenal arterial EDV and RI was found for early detection of DN (P ~ < .05). Intrarenal arterial RI and EDV showed positive correlations with UAER, FPG, uric acid, homocysteine, beta-2-microglobulin, cystatin C, HbA1c, and CRP (P ~ < .05). CONCLUSION: Color doppler ultrasound markers of renal and intrarenal arteries has a high diagnostic value for DN at its early stage.  DOI: 10.52547/ijkd.7246.

Downregulation of miR-17 suppresses TGF-ß1-mediated renal fibrosis through targeting Smad7.

MiR-17 is found upregulated in diabetic mice; however, its effect(s) on renal fibrosis of diabetic nephropathy remain(s) unknown. This study aimed to explore the mechanism underlying the downregulation of miR-17 in renal fibrosis of diabetic nephropathy (DN). Patients with diabetes mellitus (DM) and DN and normal healthy individual controls, mice (db/db, db/m), and human mesangial cells (HMCs) and human proximal tubule epithelial cells (HK-2) were used as research subjects in the study. Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to measure the expression of miR-17 in the serum samples, renal tissues and cells. Acid-Schiff (PAS) and Masson staining experiments were performed to detect glomerular mesangial matrix and collagen deposition. Levels of fibrosis-related proteins (E-Cadherin (E-cad), vimentin, fibronectin and collagen I) were measured by Western blot (WB). The target gene of miR-17 was predicted by TargetScan 7.2 and confirmed by dual-luciferase reporter analysis. The study found that miR-17 expression was elevated in the serums of DN patients as well as in the serums and kidney tissues of db/db mice. db/db mice showed a severe renal fibrosis condition. The levels of E-cad in db/db mice, HMC and HK-2 cells were increased by downregulating miR-17 expression, while expressions of vimentin, fibronectin and collagen I were reduced. Smad7 was predicted to be the target gene of miR-17, and its expression was promoted by downregulation of miR-17. Moreover, the reduced Smad7 expression could inhibit the expressions of fibrosis-related proteins, which, however, can be ameliorated by the downregulation of miR-17. In addition, downregulation of miR-17 could suppress renal fibrosis mediated by TGF-ß1 through targeting Smad7, which might be a clinical therapeutic target for patients with DN.

Effect of lipid lowering tablet on blood lipid in hyperlipidemia model rats.

Observe the effect of lipid-lowering tablets on body weight, liver index and serum biochemical indexes of hyperlipidemia rats. The hyperlipidemia rat model was replicated successfully. Compared with the model group, high, medium and low dose lipid-lowering tablets group could significantly increase the body weight of rats with hyperlipidemia (P < 0.01, P < 0.05); High and middle dose lipid-lowering tablets group could significantly reduce the liver index of high fat rat (P < 0.01); High, medium and low dose lipid-lowering tablets group could significantly decrease levels of TC, TG, LDL-C, AST, ALT, ALP, Y-GT in serum (P < 0.01, P < 0.05), and significantly increase the level of HDL-C (P < 0.01). Lipid-lowering tablets can effectively regulate the body lipid metabolism of rats, and have a certain therapeutic effect on hyperlipidemia.